Skip to content
AdminOct 7, 2019< 1 min read

Real-world evidence: Sponsors look to US FDA drug reviews for potential pitfalls

Methodological problems with RWE submissions for approved applications may give sponsors ‘a little bit of a pause’ as they work through data selection and analytical issues, Aetion’s Jeremy Rassen says. CDER’s Janet Woodcock says it is easier to use RWE when treatment effects are large.

Read More

RELATED ARTICLES